=> d l2; d his; log y
L2 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.
L2 QUE ABB=ON PLU=ON L1

(FILE 'HOME' ENTERED AT 11:42:49 ON 14 APR 2006)

FILE 'REGISTRY' ENTERED AT 11:43:01 ON 14 APR 2006
L1 STRUCTURE UPLOADED
L2 QUE L1
L3 7 S L2
L4 92 S L2 FUL

FILE 'CAPLUS' ENTERED AT 11:43:43 ON 14 APR 2006
L5 7 S L4

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	36.69	203.84

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-5.25	-5.25

STN INTERNATIONAL LOGOFF AT 11:44:56 ON 14 APR 2006

Clark 10/762,107

L5 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1281377 CAPLUS Full-text
DN 144:36379
TI Preparation of dibenzodiazepinone analogs and their use as antineoplastic agents
IN Mcalpine, James B.; Banskota, Arjun H.
PA Ecopia Biosciences Inc., Can.
SO Can. Pat. Appl., 152 pp.
CODEN: CPXXEB
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CA 2511750	AA	20051203	CA 2005-2511750	20050721
	US 2006079509	A1	20060413	US 2005-235398	20050927
	US 2006079512	A1	20060413	US 2005-253658	20051020
PRAI	US 2004-625653P	P	20041108		
	US 2005-647381P	P	20050128		
	CA 2005-2497031	A	20050211		
	US 2003-441126P	P	20030121		
	US 2003-492997P	P	20030807		
	US 2003-518286P	P	20031110		
	US 2004-762107	A1	20040121		
	US 2005-701472P	P	20050722		

OS MARPAT 144:36379
GI





I



II

AB This invention relates to novel dibenzodiazepinone analogs I [W1-W3 = independently CHR5CMeR6, CH:CMe, epoxide group Q; or the chain terminates at W1-W3 with W1-W3 = CHO, CH(OC1-6 alkyl)2, CH2OH, CH2OC1-6 alkyl, CO2R7; R1-R4 = independently H, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, CHO, etc. R5, R6 = independently H, OH, alkoxy, NH2, alkylamino, dialkylamino, acylamino; R7 = H, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-10

cycloalkyl, C3-10 heterocycloalkyl; X1-X5 = H; or one of X1-X5 = halo and the remaining = H], and to pharmaceutically acceptable salts, solvates and prodrugs, to pharmaceutical compns. comprising them, and to methods for obtaining such compds. One method of obtaining the dibenzodiazepinone analogs is by post-biosynthesis chemical modifications of the farnesyl dibenzodiazepinone ECO-4601 (II). The dibenzodiazepinone analogs are useful as pharmaceuticals, in particular as antineoplastic agents.

IT **733035-26-2P**, ECO 4601
RL: BPN (Biosynthetic preparation); PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of dibenzodiazepinone analogs and their use as antineoplastic agents)

RN 733035-26-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **733011-10-4P 733011-11-5P 733011-12-6P**
733011-13-7P 733011-14-8P 733011-15-9P
733011-16-0P 733011-17-1P 733011-18-2P
733011-20-6P 733011-21-7P 733011-22-8P
733011-23-9P 733011-24-0P 733011-25-1P
733011-26-2P 733011-27-3P 733011-28-4P
733011-29-5P 733011-30-8P 733011-31-9P
733011-32-0P 733011-33-1P 733011-34-2P
733011-35-3P 733011-36-4P 733011-37-5P
733011-38-6P 733011-39-7P 733011-41-1P
733011-42-2P 733011-43-3P 733011-44-4P
733011-45-5P 733011-46-6P 733011-47-7P
733011-48-8P 733011-49-9P 733011-50-2P
733011-51-3P 733011-52-4P 733011-59-1P
733011-60-4P 733011-61-5P 733011-62-6P
733011-64-8P 733024-75-4P 733024-76-5P
733024-77-6P 733024-78-7P 870702-19-5P
870702-20-8P 870702-21-9P 870702-22-0P
870702-23-1P 870702-24-2P 870702-25-3P
870702-26-4P 870702-27-5P 870702-28-6P
870702-29-7P 870702-30-0P 870702-31-1P
870702-32-2P 870702-33-3P 870702-34-4P
870702-35-5P 870702-36-6P 870702-37-7P
870702-38-8P 870702-39-9P 870702-40-2P
870702-41-3P 870702-42-4P 870702-43-5P
870702-44-6P 870702-45-7P 870702-46-8P
870702-47-9P 870702-48-0P 870702-49-1P
870702-50-4P 870702-51-5P 870702-52-6P

870702-53-7P 870702-54-8P 870702-58-2P
870702-59-3P
RL: BPN (Biosynthetic preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of dibenzodiazepinone analogs and their use as antineoplastic agents)

RN 733011-10-4 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-acetyl-5,10-dihydro-4,6,8-trihydroxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-11-5 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-5-(phenylmethyl)-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-12-6 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-ethyl-5,10-dihydro-4,6,8-trihydroxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-13-7 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-acetyl-4,6,8-tris(acetyloxy)-5,10-dihydro-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-14-8 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 10-[[3-[(3E)-4,8-dimethyl-3,7-nonadienyl]-3-methyloxiranyl]methyl]-5,10-dihydro-4,6,8-trihydroxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-15-9 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-[(2E)-3-methyl-5-[3-methyl-3-(4-methyl-3-pentenyl)oxiranyl]-2-pentenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-16-0 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 10-[(2E,6E)-9-(3,3-dimethyloxiranyl)-3,7-dimethyl-2,6-nonadienyl]-5,10-dihydro-4,6,8-trihydroxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-17-1 CAPLUS
CN Octitol, 2,3:6,7-dianhydro-1,4,5,8-tetradeoxy-1-(5,11-dihydro-4,6,8-trihydroxy-11-oxo-10H-dibenzo[b,e][1,4]diazepin-10-yl)-3-C-methyl-7-C-(4-methyl-3-pentenyl)- (9CI) (CA INDEX NAME)



RN 733011-18-2 CAPLUS
CN Dodecitol, 2,3:6,7:10,11-trianhydro-1,4,5,8,9,12-hexadeoxy-1-(5,11-dihydro-4,6,8-trihydroxy-11-oxo-10H-dibenzo[b,e][1,4]diazepin-10-yl)-3,7,11-tri-C-methyl- (9CI) (CA INDEX NAME)



RN 733011-20-6 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-[(2E)-3-methyl-5-[3-methyl-3-(4-methylpentyl)oxiranyl]-2-pentenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-21-7 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 10-[(2E)-9-(3,3-dimethyloxiranyl)-3,7-dimethyl-2-nonenyl]-5,10-dihydro-4,6,8-trihydroxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-22-8 CAPLUS
CN Octitol, 2,3:6,7-dianhydro-1,4,5,8-tetradeoxy-1-(5,11-dihydro-4,6,8-

trihydroxy-11-oxo-10H-dibenzo[b,e][1,4]diazepin-10-yl)-3-C-methyl-7-C-(4-methylpentyl)- (9CI) (CA INDEX NAME)



RN 733011-23-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 10-[[3-[6-(3,3-dimethyloxiranyl)-4-methylhexyl]-3-methyloxiranyl]methyl]-5,10-dihydro-4,6,8-trihydroxy- (9CI) (CA INDEX NAME)



RN 733011-24-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 10-[5-[3-[2-(3,3-dimethyloxiranyl)ethyl]-3-methyloxiranyl]-3-methylpentyl]-5,10-dihydro-4,6,8-trihydroxy- (9CI) (CA INDEX NAME)



RN 733011-25-1 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 10-[[3-(4,8-dimethyl-7-nonenyl)-3-methyloxiranyl]methyl]-5,10-dihydro-4,6,8-trihydroxy- (9CI) (CA INDEX NAME)



RN 733011-26-2 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-[3-methyl-5-[3-methyl-3-(4-methyl-3-pentenyl)oxiranyl]pentyl]- (9CI) (CA INDEX NAME)



RN 733011-27-3 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 10-[(6E)-9-(3,3-dimethyloxiranyl)-3,7-dimethyl-6-nonenyl]-5,10-dihydro-4,6,8-trihydroxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-28-4 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 10-[[3-(4,8-dimethylnonyl)-3-methyloxiranyl]methyl]-5,10-dihydro-4,6,8-trihydroxy- (9CI) (CA INDEX NAME)



RN 733011-29-5 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-[3-methyl-5-[3-methyl-3-(4-methylpentyl)oxiranyl]pentyl]- (9CI) (CA INDEX NAME)



RN 733011-30-8 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 10-[9-(3,3-dimethyloxiranyl)-3,7-dimethylnonyl]-5,10-dihydro-4,6,8-trihydroxy- (9CI) (CA INDEX NAME)





RN 733011-31-9 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 4-(acetyloxy)-5,10-dihydro-6,8-dihydroxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-32-0 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 6-(acetyloxy)-5,10-dihydro-4,8-dihydroxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-33-1 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-(acetyloxy)-5,10-dihydro-4,6-dihydroxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-34-2 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 4,6,8-tris(acetyloxy)-5,10-dihydro-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-35-3 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 6,8-bis(acetyloxy)-5,10-dihydro-4-hydroxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-36-4 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 4,8-bis(acetyloxy)-5,10-dihydro-6-hydroxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-37-5 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 4,6-bis(acetyloxy)-5,10-dihydro-8-hydroxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-38-6 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-6,8-dihydroxy-4-methoxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-39-7 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,8-dihydroxy-6-methoxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-41-1 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6-dihydroxy-8-methoxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-42-2 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trimethoxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-43-3 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4-hydroxy-6,8-dimethoxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-44-4 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-6-hydroxy-4,8-dimethoxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-45-5 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-hydroxy-4,6-dimethoxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-46-6 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-[(6E)-3,7,11-trimethyl-6,10-dodecadienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-47-7 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-[(2E)-3,7,11-trimethyl-2,10-dodecadienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-48-8 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-[(2E,6E)-3,7,11-trimethyl-2,6-dodecadienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-49-9 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-(3,7,11-trimethyl-10-dodecenyl)- (9CI) (CA INDEX NAME)



RN 733011-50-2 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-[(6E)-3,7,11-trimethyl-6-dodecenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-51-3 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-[(2E)-3,7,11-trimethyl-2-dodecenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-52-4 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-(3,7,11-trimethyldodecyl)- (9CI) (CA INDEX NAME)



RN 733011-59-1 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 10-[(6E)-2,3-dihydroxy-3,7,11-trimethyl-6,10-dodecadienyl]-5,10-dihydro-4,6,8-trihydroxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-60-4 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 10-[(2E)-6,7-dihydroxy-3,7,11-trimethyl-2,10-dodecadienyl]-5,10-dihydro-4,6,8-trihydroxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-61-5 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 10-[(2E,6E)-10,11-dihydroxy-3,7,11-trimethyl-2,6-dodecadienyl]-5,10-dihydro-4,6,8-trihydroxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-62-6 CAPLUS
CN Octitol, 1,4,5,8-tetradeoxy-1-(5,11-dihydro-4,6,8-trihydroxy-11-oxo-10H-dibenzo[b,e][1,4]diazepin-10-yl)-3-C-methyl-7-C-(4-methyl-3-pentenyl)- (9CI) (CA INDEX NAME)



RN 733011-64-8 CAPLUS
CN Dodecitol, 1,4,5,8,9,12-hexadeoxy-1-(5,11-dihydro-4,6,8-trihydroxy-11-oxo-10H-dibenzo[b,e][1,4]diazepin-10-yl)-3,7,11-tri-C-methyl- (9CI) (CA INDEX NAME)



RN 733024-75-4 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 10-[[3-[(3E)-6-(3,3-dimethyloxiranyl)-4-methyl-3-hexenyl]-3-methyloxiranyl]methyl]-5,10-dihydro-4,6,8-trihydroxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733024-76-5 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 10-[(2E)-5-[3-[2-(3,3-dimethyloxiranyl)ethyl]-3-methyloxiranyl]-3-methyl-2-pentenyl]-5,10-dihydro-4,6,8-trihydroxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733024-77-6 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-[(6E)-2,3,10,11-tetrahydroxy-3,7,11-trimethyl-6-dodecenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733024-78-7 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-[(2E)-6,7,10,11-tetrahydroxy-3,7,11-trimethyl-2-dodecenyl]- (9CI) (CA

INDEX NAME)

Double bond geometry as shown.



RN 870702-19-5 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-5-methyl-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 870702-20-8 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 10-[[3-[(3E)-4,8-dimethyl-3-nonenyl]-3-methyloxiranyl]methyl]-5,10-dihydro-4-hydroxy-6,8-dimethoxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 870702-21-9 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-5-(1-

methyl-2-propenyl)-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 870702-22-0 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-5-(2-
methyl-1-propenyl)-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 870702-23-1 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-(2-butenyl)-5,10-dihydro-4,6,8-
trihydroxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA
INDEX NAME)

Double bond geometry as described by E or Z.



RN 870702-24-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-5-propyl-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 870702-25-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-butyl-5,10-dihydro-4,6,8-trihydroxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 870702-26-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-5-(2-methylbutyl)-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 870702-27-5 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-(1,1-dimethylethyl)-5,10-dihydro-4,6,8-trihydroxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 870702-28-6 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-hexyl-5,10-dihydro-4,6,8-trihydroxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 870702-29-7 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-5-octyl-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 870702-30-0 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-5-(trifluoromethyl)-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 870702-31-1 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-(heptafluoropropyl)-5,10-dihydro-4,6,8-trihydroxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 870702-32-2 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-5-[1,2,2,2-tetrafluoro-1-(trifluoromethyl)ethyl]-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 870702-33-3 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-5-(pentafluoroethyl)-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 870702-34-4 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-cyclopropyl-5,10-dihydro-4,6,8-trihydroxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 870702-35-5 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-cyclohexyl-5,10-dihydro-4,6,8-trihydroxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 870702-36-6 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-5-(2-phenylethyl)-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 870702-37-7 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-5-(3-phenylpropyl)-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 870702-38-8 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-5-(1-methylpropyl)-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI)

(CA INDEX NAME)

Double bond geometry as shown.



RN 870702-39-9 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-5-methyl-10-(3,7,11-trimethyldodecyl)- (9CI) (CA INDEX NAME)



RN 870702-40-2 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-[(2E,6E)-11-methoxy-3,7,11-trimethyl-2,6-dodecadienyl]-5-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 870702-41-3 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-[(2E)-7-methoxy-3,7,11-trimethyl-2,10-dodecadienyl]-5-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 870702-42-4 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 10-[(2E)-7,11-dimethoxy-3,7,11-trimethyl-2-dodecenyl]-5,10-dihydro-4,6,8-trihydroxy-5-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 870702-43-5 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-[(2E,6E)-11-methoxy-3,7,11-trimethyl-2,6-dodecadienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 870702-44-6 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-[(2E)-7-methoxy-3,7,11-trimethyl-2,10-dodecadienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 870702-45-7 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 10-[(2E)-7,11-dimethoxy-3,7,11-trimethyl-2-dodecenyl]-5,10-dihydro-4,6,8-trihydroxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 870702-46-8 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-ethyl-5,10-dihydro-4,6,8-trihydroxy-10-[(2E,6E)-11-methoxy-3,7,11-trimethyl-2,6-dodecadienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 870702-47-9 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-ethyl-5,10-dihydro-4,6,8-trihydroxy-10-[(2E)-7-methoxy-3,7,11-trimethyl-2,10-dodecadienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 870702-48-0 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 10-[(2E)-7,11-dimethoxy-3,7,11-trimethyl-2-dodecenyl]-5-ethyl-5,10-dihydro-4,6,8-trihydroxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 870702-49-1 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-[(2E,6E)-11-hydroxy-3,7,11-trimethyl-2,6-dodecadienyl]-5-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 870702-50-4 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-[(2E)-7-hydroxy-3,7,11-trimethyl-2,10-dodecadienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 870702-51-5 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 10-[(2E)-7,11-dihydroxy-3,7,11-trimethyl-2-dodecenyl]-5,10-dihydro-4,6,8-trihydroxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 870702-52-6 CAPLUS
CN Acetamide, N-[(5E,9E)-11-(5,11-dihydro-4,6,8-trihydroxy-5-methyl-11-oxo-10H-dibenzo[b,e][1,4]diazepin-10-yl)-1,1,5,9-tetramethyl-5,9-undecadienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 870702-53-7 CAPLUS
CN Acetamide, N-[(5E)-7-(5,11-dihydro-4,6,8-trihydroxy-11-oxo-10H-dibenzo[b,e][1,4]diazepin-10-yl)-1,5-dimethyl-1-(4-methyl-3-pentenyl)-5-heptenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 870702-54-8 CAPLUS

CN Acetamide, N,N'-[1-[(4E)-6-(5,11-dihydro-4,6,8-trihydroxy-11-oxo-10H-dibenzo[b,e][1,4]diazepin-10-yl)-4-methyl-4-hexenyl]-1,5,5-trimethyl-1,5-pentanediyl]bis- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 870702-58-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-bromo-5,10-dihydro-4,6,8-trihydroxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 870702-59-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-5-(methyl-d3)-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L5 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:502554 CAPLUS Full-text
DN 143:282312
TI Revision of the structure assigned to the antibiotic BU-4664L from Micromonopora
AU Igarashi, Yasuhiro; Miyanaga, Satoshi; Onaka, Hiroyasu; Takeshita, Michinori; Furumai, Tamotsu
CS Biotechnology Research Center, Toyama Prefectural University, Toyama, 939-0398, Japan
SO Journal of Antibiotics (2005), 58(5), 350-352
CODEN: JANTAJ; ISSN: 0021-8820
PB Japan Antibiotics Research Association
DT Journal
LA English
AB The structure assigned to the antitumor antibiotic BU-4664L from Micromonospora sp. was revised to 5,10-dihydro-4,6,8-trihydroxy-10-(3,7,11-trimethyl-trans-2,trans-6,10-dodecatrienyl)-11H-dibenzo[b,e][1,4]diazepin- 11-one based on the NMR anal.
IT **733035-26-2**
RL: PRP (Properties)
(revision of the structure assigned to the antibiotic BU-4664L from Micromonopora)
RN 733035-26-2 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:431399 CAPLUS Full-text
DN 142:482166
TI Preparation of farnesyl dibenzodiazepinones, their production with microorganisms, and their use as antitumor, antibacterial, and antiinflammatory agents
IN Farnet, Chris M.; Dimitriadou, Violetta; Bachmann, Brian O.
PA Ecopia Biosciences, Inc., USA
SO U.S. Pat. Appl. Publ., 44 pp., Cont.-in-part of U.S. Ser. No. 762,107.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005107363	A1	20050519	US 2004-951436	20040927
	US 2005043297	A1	20050224	US 2004-762107	20040121
	CA 2507567	AA	20051113	CA 2005-2507567	20050516
	WO 2006034567	A1	20060406	WO 2005-CA751	20050516
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	US 2006079508	A1	20060413	US 2005-130295	20050516
	WO 2006034574	A1	20060406	WO 2005-CA1467	20050926
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	US 2006079509	A1	20060413	US 2005-235398	20050927
	US 2006079512	A1	20060413	US 2005-253658	20051020
PRAI	US 2003-441126P	P	20030121		
	US 2003-492997P	P	20030807		
	US 2003-518286P	P	20031110		
	US 2004-762107	A2	20040121		
	US 2004-951436	A	20040927		
	US 2004-625653P	P	20041108		
	US 2005-647381P	P	20050128		
	CA 2005-2497031	A	20050211		
	US 2005-701472P	P	20050722		

OS MARPAT 142:482166
GI



I

AB This invention relates to the prepn of farnesyl dibenzodiazepinone derivs., such as I [R = H, alkyl, alkenyl, aryl, heteroaryl; R1, R2, R3 = H, alkyl, alkenyl, aryl, heteroaryl, acyl; X, X1, X2 = H2, (OH)2, -O-, or forms (E)-double bond], to methods of their use inhibiting the growth of cancer cells and to methods of treating cancer using the farnesylated dibenzodiazepinones. Thus, farnesyl dibenzodiazepinone I [R = R1 = R2 = R3 = H, X = X1 = X2 forms (E)-double bond] (ECO 04601) was prepared via a fermentation process using Micromonosproa spp. and was subsequently epoxidized with m-chloroperbenzoic acid in THF to form corresponding mono-epoxides II [R = R1 = R2 = R3 = H, X = -O-, X1 = X2 forms (E)-double bond; X = X2 forms (E)-double bond, X1 = -O-; X = X1 forms (E)-double bond, X2 = -O-] with yields ranging from 15 to 25%. ECO 04601 was tested for anticancer activity against a variety of cancer cell lines.

IT **733035-26-2P**, ECO 04601
RL: BPN (Biosynthetic preparation); PAC (Pharmacological activity); PKT (Pharmacokinetics); PUR (Purification or recovery); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of farnesyl dibenzodiazepinones, their production with Micromonospora microorganisms, and their use as antitumor, antibacterial, and antiinflammatory agents)

RN 733035-26-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **733011-10-4P 733011-11-5P 733011-12-6P**
733011-13-7P 733011-14-8P 733011-15-9P
733011-16-0P 733011-17-1P 733011-18-2P
733011-19-3P 733011-20-6P 733011-24-0P
733011-31-9P 733011-32-0P 733011-33-1P
733011-38-6P 733011-39-7P 733011-41-1P
733011-46-6P 733011-47-7P 733011-48-8P
733011-49-9P 733011-50-2P 733011-51-3P

733011-52-4P 733011-59-1P 733024-75-4P
733024-76-5P
RL: BPN (Biosynthetic preparation); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of farnesyl dibenzodiazepinones, their production with Micromonospora microorganisms, and their use as antitumor, antibacterial, and antiinflammatory agents)

RN 733011-10-4 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-acetyl-5,10-dihydro-4,6,8-trihydroxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-11-5 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-5-(phenylmethyl)-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-12-6 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-ethyl-5,10-dihydro-4,6,8-trihydroxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-13-7 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-acetyl-4,6,8-tris(acetyloxy)-5,10-dihydro-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-14-8 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 10-[[3-[(3E)-4,8-dimethyl-3,7-nonadienyl]-3-methyloxiranyl]methyl]-5,10-dihydro-4,6,8-trihydroxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-15-9 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-[(2E)-3-methyl-5-[3-methyl-3-(4-methyl-3-pentenyl)oxiranyl]-2-pentenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-16-0 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 10-[(2E,6E)-9-(3,3-dimethyloxiranyl)-3,7-dimethyl-2,6-nonadienyl]-5,10-dihydro-4,6,8-trihydroxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-17-1 CAPLUS
CN Octitol, 2,3:6,7-dianhydro-1,4,5,8-tetradeoxy-1-(5,11-dihydro-4,6,8-trihydroxy-11-oxo-10H-dibenzo[b,e][1,4]diazepin-10-yl)-3-C-methyl-7-C-(4-methyl-3-pentenyl)- (9CI) (CA INDEX NAME)



RN 733011-18-2 CAPLUS
CN Dodecitol, 2,3:6,7:10,11-trianhydro-1,4,5,8,9,12-hexadeoxy-1-(5,11-dihydro-4,6,8-trihydroxy-11-oxo-10H-dibenzo[b,e][1,4]diazepin-10-yl)-3,7,11-tri-C-methyl- (9CI) (CA INDEX NAME)



RN 733011-19-3 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 10-[[3-[(3E)-4,8-dimethyl-3-nonenyl]-3-methyloxiranyl]methyl]-5,10-dihydro-4,6,8-trihydroxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-20-6 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-[(2E)-3-methyl-5-[3-methyl-3-(4-methylpentyl)oxiranyl]-2-pentenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-24-0 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 10-[5-[3-[2-(3,3-dimethyloxiranyl)ethyl]-3-methyloxiranyl]-3-methylpentyl]-5,10-dihydro-4,6,8-trihydroxy- (9CI) (CA INDEX NAME)



RN 733011-31-9 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 4-(acetyloxy)-5,10-dihydro-6,8-dihydroxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-32-0 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 6-(acetyloxy)-5,10-dihydro-4,8-dihydroxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-33-1 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-(acetyloxy)-5,10-dihydro-4,6-dihydroxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-38-6 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-6,8-dihydroxy-4-methoxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-39-7 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,8-dihydroxy-6-methoxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-41-1 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6-dihydroxy-8-methoxy-

10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-46-6 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-[(6E)-3,7,11-trimethyl-6,10-dodecadienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-47-7 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-[(2E)-3,7,11-trimethyl-2,10-dodecadienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-48-8 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-

[(2E,6E)-3,7,11-trimethyl-2,6-dodecadienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-49-9 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-(3,7,11-trimethyl-10-dodecenyl)- (9CI) (CA INDEX NAME)



RN 733011-50-2 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-[(6E)-3,7,11-trimethyl-6-dodecenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-51-3 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-[(2E)-3,7,11-trimethyl-2-dodecenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-52-4 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-(3,7,11-trimethyldodecyl)- (9CI) (CA INDEX NAME)



RN 733011-59-1 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 10-[(6E)-2,3-dihydroxy-3,7,11-trimethyl-6,10-dodecadienyl]-5,10-dihydro-4,6,8-trihydroxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733024-75-4 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 10-[[3-[(3E)-6-(3,3-dimethyloxiranyl)-4-methyl-3-hexenyl]-3-methyloxiranyl]methyl]-5,10-dihydro-4,6,8-trihydroxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733024-76-5 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 10-[(2E)-5-[3-[2-(3,3-dimethyloxiranyl)ethyl]-3-methyloxiranyl]-3-methyl-2-pentenyl]-5,10-dihydro-4,6,8-trihydroxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L5 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:159568 CAPLUS Full-text
DN 143:382454
TI Marine actinomycetes as a source of novel secondary metabolites
AU Fiedler, Hans-Peter; Bruntner, Christina; Bull, Alan T.; Ward, Alan C.; Goodfellow, Michael; Potterat, Olivier; Puder, Carsten; Mihm, Gerhard
CS Mikrobiologisches Institut, Universitaet Tuebingen, Tuebingen, D-72076, Germany
SO Antonie van Leeuwenhoek (2005), 87(1), 37-42
CODEN: ALJMAO; ISSN: 0003-6072
PB Springer
DT Journal
LA English
AB A set of 600 actinomycetes strains which were isolated from marine sediments from various sites in the Pacific and Atlantic Oceans were screened for the production of bioactive secondary metabolites. Marine streptomycete strains were found to be producers of well known chemical diverse antibiotics isolated from terrestrial streptomycetes, as in the case of marine Micromonospora strains. New marine members of the rare genus Verrucosispora seem to be a promising source for novel bioactive secondary metabolites as shown in the case of the abyssomicin producing strain AB-18-032.
IT **733035-26-2**, BU 4664L
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(marine actinomycetes as a source of novel secondary metabolites)
RN 733035-26-2 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:634064 CAPLUS Full-text
DN 141:167757
TI Farnesyl dibenzodiazepinones, their production with microorganisms, and their use as antitumor, antibacterial, and antiinflammatory agents
IN Bachmann, Brian O.; Mcalpine, James B.; Zazopoulos, Emmanuel; Farnet, Chris M.; Piraee, Mahmood
PA Ecopia Biosciences Inc., Can.
SO PCT Int. Appl., 269 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004065591	A1	20040805	WO 2004-CA69	20040121
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
	AU 2004206046	A1	20040805	AU 2004-206046	20040121
	CA 2466340	AA	20040809	CA 2004-2466340	20040121
	EP 1585814	A1	20051019	EP 2004-703733	20040121
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2006079509	A1	20060413	US 2005-235398	20050927
	US 2006079512	A1	20060413	US 2005-253658	20051020
PRAI	US 2003-441126P	P	20030121		
	US 2003-492997P	P	20030807		
	US 2003-518286P	P	20031110		
	US 2004-762107	A1	20040121		
	WO 2004-CA69	A	20040121		
	US 2004-625653P	P	20041108		
	US 2005-647381P	P	20050128		
	CA 2005-2497031	A	20050211		
	US 2005-701472P	P	20050722		

OS MARPAT 141:167757
AB This invention relates to a novel farnesylated dibenzodiazepinone, named ECO-04601, its pharmaceutically acceptable salts and derivs., and to methods for obtaining such compds. One method of obtaining the ECO-04601 compound is by cultivation of a novel strain of Micromonospora sp., 046-ECO11; another method involves expression of biosynthetic pathway genes in transformed host cells. The present invention further relates to Micromonospora sp. strain 046-ECO11, to the use of ECO-04601 and its pharmaceutically acceptable salts and derivs. as pharmaceuticals, in particular to their use as inhibitors of cancer cell growth, bacterial cell growth, mammalian lipoxygenase, and to pharmaceutical compns. comprising ECO-04601 or a pharmaceutically acceptable salt or derivative thereof. Finally, the invention relates to novel polynucleotide sequences and their encoded proteins, which are involved in the biosynthesis of ECO-04601.
IT **733035-26-2P**, ECO 04601
RL: BMF (Bioindustrial manufacture); BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(farnesyl dibenzodiazepinones, their production with microorganisms, and their use as antitumor, antibacterial, and antiinflammatory agents)
RN 733035-26-2 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **733011-10-4P 733011-11-5P 733011-12-6P**
733011-13-7P 733011-14-8P 733011-15-9P
733011-16-0P 733011-17-1P 733011-18-2P
733011-19-3P 733011-20-6P 733011-21-7P
733011-22-8P 733011-23-9P 733011-24-0P
733011-25-1P 733011-26-2P 733011-27-3P
733011-28-4P 733011-29-5P 733011-30-8P
733011-31-9P 733011-32-0P 733011-33-1P
733011-34-2P 733011-35-3P 733011-36-4P
733011-37-5P 733011-38-6P 733011-39-7P
733011-41-1P 733011-42-2P 733011-43-3P
733011-44-4P 733011-45-5P 733011-46-6P
733011-47-7P 733011-48-8P 733011-49-9P
733011-50-2P 733011-51-3P 733011-52-4P
733011-59-1P 733011-60-4P 733011-61-5P
733011-62-6P 733011-64-8P 733024-75-4P
733024-76-5P 733024-77-6P 733024-78-7P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(farnesyl dibenzodiazepinones, their production with microorganisms, and their use as antitumor, antibacterial, and antiinflammatory agents)

RN 733011-10-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-acetyl-5,10-dihydro-4,6,8-trihydroxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-11-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-5-(phenylmethyl)-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-12-6 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-ethyl-5,10-dihydro-4,6,8-trihydroxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-13-7 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-acetyl-4,6,8-tris(acetyloxy)-5,10-dihydro-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-14-8 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 10-[[3-[(3E)-4,8-dimethyl-3,7-nonadienyl]-3-methyloxiranyl]methyl]-5,10-dihydro-4,6,8-trihydroxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-15-9 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-[(2E)-3-methyl-5-[3-methyl-3-(4-methyl-3-pentenyl)oxiranyl]-2-pentenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-16-0 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 10-[(2E,6E)-9-(3,3-dimethyloxiranyl)-3,7-dimethyl-2,6-nonadienyl]-5,10-dihydro-4,6,8-trihydroxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-17-1 CAPLUS
CN Octitol, 2,3:6,7-dianhydro-1,4,5,8-tetradeoxy-1-(5,11-dihydro-4,6,8-trihydroxy-11-oxo-10H-dibenzo[b,e][1,4]diazepin-10-yl)-3-C-methyl-7-C-(4-methyl-3-pentenyl)- (9CI) (CA INDEX NAME)



RN 733011-18-2 CAPLUS
CN Dodecitol, 2,3:6,7:10,11-trianhydro-1,4,5,8,9,12-hexadeoxy-1-(5,11-dihydro-4,6,8-trihydroxy-11-oxo-10H-dibenzo[b,e][1,4]diazepin-10-yl)-3,7,11-tri-C-methyl- (9CI) (CA INDEX NAME)



RN 733011-19-3 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 10-[[3-[(3E)-4,8-dimethyl-3-nonenyl]-3-methyloxiranyl]methyl]-5,10-dihydro-4,6,8-trihydroxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-20-6 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-

[(2E)-3-methyl-5-[3-methyl-3-(4-methylpentyl)oxiranyl]-2-pentenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-21-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 10-[(2E)-9-(3,3-dimethyloxiranyl)-3,7-dimethyl-2-nonenyl]-5,10-dihydro-4,6,8-trihydroxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-22-8 CAPLUS

CN Octitol, 2,3:6,7-dianhydro-1,4,5,8-tetradeoxy-1-(5,11-dihydro-4,6,8-trihydroxy-11-oxo-10H-dibenzo[b,e][1,4]diazepin-10-yl)-3-C-methyl-7-C-(4-methylpentyl)- (9CI) (CA INDEX NAME)



RN 733011-23-9 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 10-[[3-[6-(3,3-dimethyloxiranyl)-4-methylhexyl]-3-methyloxiranyl]methyl]-5,10-dihydro-4,6,8-trihydroxy- (9CI) (CA INDEX NAME)



RN 733011-24-0 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 10-[5-[3-[2-(3,3-dimethyloxiranyl)ethyl]-3-methyloxiranyl]-3-methylpentyl]-5,10-dihydro-4,6,8-trihydroxy- (9CI) (CA INDEX NAME)



RN 733011-25-1 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 10-[[3-(4,8-dimethyl-7-nonenyl)-3-methyloxiranyl]methyl]-5,10-dihydro-4,6,8-trihydroxy- (9CI) (CA INDEX NAME)



RN 733011-26-2 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-[3-methyl-5-[3-methyl-3-(4-methyl-3-pentenyl)oxiranyl]pentyl]- (9CI) (CA INDEX NAME)



RN 733011-27-3 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 10-[(6E)-9-(3,3-dimethyloxiranyl)-3,7-dimethyl-6-nonenyl]-5,10-dihydro-4,6,8-trihydroxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-28-4 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 10-[[3-(4,8-dimethylnonyl)-3-methyloxiranyl]methyl]-5,10-dihydro-4,6,8-trihydroxy- (9CI) (CA INDEX NAME)



RN 733011-29-5 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-[3-methyl-5-[3-methyl-3-(4-methylpentyl)oxiranyl]pentyl]- (9CI) (CA INDEX NAME)



RN 733011-30-8 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 10-[9-(3,3-dimethyloxiranyl)-3,7-dimethylnonyl]-5,10-dihydro-4,6,8-trihydroxy- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 733011-31-9 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 4-(acetyloxy)-5,10-dihydro-6,8-dihydroxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-32-0 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 6-(acetyloxy)-5,10-dihydro-4,8-dihydroxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-33-1 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-(acetyloxy)-5,10-dihydro-4,6-dihydroxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-34-2 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 4,6,8-tris(acetyloxy)-5,10-dihydro-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-35-3 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 6,8-bis(acetyloxy)-5,10-dihydro-4-hydroxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-36-4 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 4,8-bis(acetyloxy)-5,10-dihydro-6-hydroxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-37-5 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 4,6-bis(acetyloxy)-5,10-dihydro-8-hydroxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-38-6 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-6,8-dihydroxy-4-methoxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-39-7 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,8-dihydroxy-6-methoxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-41-1 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6-dihydroxy-8-methoxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-42-2 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trimethoxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-43-3 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4-hydroxy-6,8-dimethoxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-44-4 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-6-hydroxy-4,8-dimethoxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-45-5 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-hydroxy-4,6-dimethoxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-46-6 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-[(6E)-3,7,11-trimethyl-6,10-dodecadienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-47-7 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-[(2E)-3,7,11-trimethyl-2,10-dodecadienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-48-8 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-[(2E,6E)-3,7,11-trimethyl-2,6-dodecadienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-49-9 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-(3,7,11-trimethyl-10-dodecenyl)- (9CI) (CA INDEX NAME)



RN 733011-50-2 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-[(6E)-3,7,11-trimethyl-6-dodecenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-51-3 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-[(2E)-3,7,11-trimethyl-2-dodecenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-52-4 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-(3,7,11-trimethyldodecyl)- (9CI) (CA INDEX NAME)



RN 733011-59-1 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 10-[(6E)-2,3-dihydroxy-3,7,11-trimethyl-6,10-dodecadienyl]-5,10-dihydro-4,6,8-trihydroxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-60-4 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 10-[(2E)-6,7-dihydroxy-3,7,11-trimethyl-2,10-dodecadienyl]-5,10-dihydro-4,6,8-trihydroxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-61-5 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 10-[(2E,6E)-10,11-dihydroxy-3,7,11-trimethyl-2,6-dodecadienyl]-5,10-dihydro-4,6,8-trihydroxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733011-62-6 CAPLUS
CN Octitol, 1,4,5,8-tetradeoxy-1-(5,11-dihydro-4,6,8-trihydroxy-11-oxo-10H-dibenzo[b,e][1,4]diazepin-10-yl)-3-C-methyl-7-C-(4-methyl-3-pentenyl)- (9CI) (CA INDEX NAME)



RN 733011-64-8 CAPLUS
CN Dodecitol, 1,4,5,8,9,12-hexadeoxy-1-(5,11-dihydro-4,6,8-trihydroxy-11-oxo-10H-dibenzo[b,e][1,4]diazepin-10-yl)-3,7,11-tri-C-methyl- (9CI) (CA INDEX NAME)



RN 733024-75-4 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 10-[[3-[(3E)-6-(3,3-dimethyloxiranyl)-4-methyl-3-hexenyl]-3-methyloxiranyl]methyl]-5,10-dihydro-4,6,8-trihydroxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733024-76-5 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 10-[(2E)-5-[3-[2-(3,3-dimethyloxiranyl)ethyl]-3-methyloxiranyl]-3-methyl-2-pentenyl]-5,10-dihydro-4,6,8-trihydroxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733024-77-6 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-[(6E)-2,3,10,11-tetrahydroxy-3,7,11-trimethyl-6-dodecenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 733024-78-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-[(2E)-6,7,10,11-tetrahydroxy-3,7,11-trimethyl-2-dodecenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:462918 CAPLUS Full-text
DN 141:170547
TI Diazepinomicin, a new antimicrobial alkaloid from a marine Micromonospora sp.
AU Charan, Romila D.; Schlingmann, Gerhard; Janso, Jeffrey; Bernan, Valerie; Feng, Xidong; Carter, Guy T.
CS Chemical and Screening Sciences, Wyeth Research, Pearl River, NY, 10965, USA
SO Journal of Natural Products (2004), 67(8), 1431-1433
CODEN: JNPRDF; ISSN: 0163-3864
PB American Chemical Society
DT Journal
LA English
GI



I

AB The structure of a new dibenzodiazepine alkaloid, diazepinomicin (I), isolated from the culture of a marine actinomycete of the genus Micromonospora, was characterized using spectroscopic methods. Diazepinomicin represents a unique mol. class composed of a dibenzodiazepine core linked to a farnesyl side chain.

IT **733035-26-2P**, Diazepinomicin
RL: BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); BIOL (Biological study); PREP (Preparation) (diazepinomicin from marine Micromonospora)
RN 733035-26-2 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1996:494734 CAPLUS Full-text
DN 125:140671
TI Compound produced by a Micromonospora strain
IN Ohkuma, Hiroaki; Kobaru, Seikichi
PA Bristol-Myers Squibb Company, USA
SO U.S., 14 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5541181	A	19960730	US 1994-249518	19940526
PRAI US 1994-249518		19940526		

OS MARPAT 125:140671
GI



I

AB Disclosed is the novel compound BU-4664L (I) and derivs. thereof. The compound is produced by fermentation of Micromonospora sp. M990-6. The compound possesses anti-inflammatory and/or anti-tumor activities.

IT **733035-26-2P**, BU 4664L
RL: BAC (Biological activity or effector, except adverse); BMF (Bioindustrial manufacture); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(anti-inflammatory and anti-tumor compound BU-4664L from Micromonospora)

RN 733035-26-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **179981-41-0P 179981-42-1P**
RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(anti-inflammatory and anti-tumor compound BU-4664L from Micromonospora)

RN 179981-41-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 4,7,9-tris(acetyloxy)-5,10-dihydro-5-(3,7,11-trimethyl-2,6,10-dodecatrienyl)-, (E,E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 179981-42-1 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,7,9-trimethoxy-5-(3,7,11-trimethyl-2,6,10-dodecatrienyl)-, (E,E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.